Concepedia

Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial

Neeta Somaiah, Anthony P. Conley, Edwin R. Parra, Heather Lin, Behrang Amini, Luisa M. Solis Soto, Ruth Salazar, Carmélia Maria Noia Barreto, Honglei Chen, Swati Gite,

The Lancet Oncology · 2022 · 157 citations · 18 references

DOI

Concepts

References

18

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley et al. · Nature · 2014 · 6.6K citations · Full text

, , +14

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

Winette T.A. van der Graaf, Jean‐Yves Blay, Sant P. Chawla et al. · The Lancet · 2012 · 2.1K citations · Full text

, , +9

Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease

Laurent Monney, Catherine A. Sabatos, Jason L. Gaglia et al. · Nature · 2002 · 1.6K citations

, , +16

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack et al. · The Lancet Oncology · 2017 · 1.4K citations · Full text

, , +13

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Rodabe N. Amaria, Sangeetha M. Reddy, Hussein A. Tawbi et al. · Nature Medicine · 2018 · 826 citations · Full text

, , +14